Table 1.
The characteristics of included RCTs
| Authors (Ref) | Publication year | Country | Intervention/control (sample size) | Duration (week) | Method of administration/Dosage | Patients | Weight change/BMI at baseline | Intervention/control (age participants) |
|---|---|---|---|---|---|---|---|---|
| Arnson at al. [19] | 2013 | Israel | 25/25 | 5 days | Oral/4000 IU 25(OH)-vitamin D/day | Patients with acute coronary syndrome | NR/NR | 61.6 ± 12.7, 59.7 ± 13.4 |
| Witham (a) et al. [17] | 2013 | Scotland | 36/39 | 6 months | Oral/ 100,000 IU vitamin D3 (0, 2 and 4 months) | Patients with a history of myocardial infarction | NR/NR | 67.5 ± 10.6, 64.3 ± 9.8 |
| Witham (b) et al. [17] | 2013 | Scotland | 36/39 | 2 months | Oral/ 100,000 IU vitamin D3 (0 and 2 month) | Patients with a history of myocardial infarction | NR/NR | 67.5 ± 10.6, 64.3 ± 9.8 |
| Salekzamani et al. [35] | 2017 | Iran | 36/35 | 16 weeks | Oral/ 50,000 IU/week for 16 weeks | Patients with metabolic syndrome | NR/33.37 ± 4.59 | 40.92 ± 5.95, 40.06 ± 4.83 |
| Dalan et al. [10] | 2016 | Singapore | 30/31 | 16 weeks | Oral/ Baseline 25(OH) D ≤ 20 ng/mL: four tablets of (4000 IU/day) Baseline 25(OH)D 21–30 ng/mL: 2000 IU/day | Patients with type 2 diabetes mellitus | NR/28.1 ± 5.9 | 54.8 ± 10.8, 52.2 ± 8.2 |
| Neyestani (a) et al. [36] | 2013 | Iran | 50/35 | 12 weeks | Oral/ Two 500 IU vitamin D for 12 weeks | Patients with type 2 diabetes with alleles Ff | No-significant/30.0 ± 5.0 | 52.4 ± 8.4, 52.6 ± 6.3 |
| Neyestani (b) et al. [36] | 2013 | Iran | 50/47 | 12 weeks | Oral/ Two 500 IU vitamin D for 12 weeks | Patients with type 2 diabetes with alleles Ff | No-significant/29.0 ± 4.2 | 52.4 ± 8.4, 52.6 ± 6.3 |
| Neyestani © et al. [36] | 2013 | Iran | 50/58 | 12 weeks | Oral/ Two 500 IU vitamin D for 12 weeks | Patients with type 2 diabetes with alleles Ff | No-significant/27.8 ± 4.7 | 52.4 ± 8.4, 52.6 ± 6.3 |
| Sokol et al. [18] | 2012 | USA | 45/45 | 12 weeks | Oral/ 50,000 IU ergocalciferol per week | Patients with coronary artery disease | NR/30.25 ± 6.9 | 56.96 ± 11.6, 55 ± 9.6 |
| Longenecker et al. [20] | 2011 | USA | 15/29 | 12 weeks | Oral/ Vitamin D3 4000 IU daily for 12 weeks | Patients with HIV-infected overweight | NR/27.5 ± 5.55 | 40 ± 10, 47 ± 8 |
| Marckmann (a) et al. [37] | 2012 | Denmark | 11/13 | 8 weeks | Oral/ 40,000 IU vitamin D3 every week for 8 weeks | Patients with chronic kidney disease | NR/25.25 ± 4.77 | 68 ± 21.68, 71 ± 20.40 |
| Marckmann (b) et al. [37] | 2012 | Denmark | 13/12 | 8 weeks | Oral/ 40,000 IU vitamin D3 every week for 8 weeks | Patients with chronic kidney disease | NR/25.25 ± 4.78 | 68 ± 21.68, 71 ± 20.40 |
| Marckmann © et al. [37] | 2012 | Denmark | 26/26 | 8 weeks | Oral/ 40,000 IU vitamin D3 every week for 8 weeks | Patients with chronic kidney disease | NR/25.25 ± 4.79 | 68 ± 21.68, 71 ± 20.40 |
| Kumar et al. [38] | 2017 | India | 59/58 | 16 weeks | Oral/ Cholecalciferol (300,000 IU) for 8 weeks | Patients with nondiabetic chronic kidney disease stage 3–4 | NR/23.51 ± 2.79 | 45.20 ± 11.61, 43.17 ± 11.79 |
| Emami Naeini et al. [39] | 2018 | Iran | 32/32 | 16 weeks | Oral/ 50,000 IU vitamin D per week for 12 weeks | End-stage renal disease patients | NR/26.8 ± 7 | 62 ± 21, 60 ± 19 |
| Assimon et al. [40] | 2012 | USA | 20/20 | 39 weeks | Oral/ 33,125 ± 17,805 IU/week for an average duration of 39.2 ± 28.3 weeks | Haemodialysis patients | NR/29.9 ± 6.5 | 64.4 ± 15.6, 68.1 ± 15.9 |
| Zhang et al. [21] | 2018 | China | 46/25 | 12 weeks | Oral/ 50,000 IU cholecalciferol once a week for 12 weeks | Patients with non-dialysis chronic kidney disease | NR/22.7 ± 2.2 | 61.8 ± 16.6, 55.5 ± 14.7 |
| Gholami et al. [41] | 2016 | Iran | 40/20 | 4 weeks | Intramuscular/ Single dose of 300,000 IU vitamin D3 | Patients with venous thromboembolism | NR/NR | 53.2 ± 17.3 |
| Borgi et al. [22] | 2017 | USA | 41/43 | 8 weeks | Oral/ 50,000 IU/week ergocalciferol for 4 weeks | Overweight or obese adults | NR/33.9 ± 5.8 | 35 ± 11, 39 ± 13 |
NR, not reported